Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has ...

Constellium's diverse operations make its observations key indicators of the aluminium industry trends—a segment in which ...

Teva receives a buy rating due to growth potential as a global generic drugmaker, despite high debt and legal/regulatory ...

Swiss pharma giant Roche is refocusing its R&D investment on diseases like obesity that weigh heavily on healthcare budgets.

Granted, each of these companies has its own, sometimes-complicated, narrative playing out, and there are particularities of ...

Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ...

Is the United States election that important? “What kind of question is that?” most people would ask. The obvious answer is a ...

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- , (Nasdaq: TVTX) ...

CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

The cost of healthcare in the U.S. remains outrageously high, despite massive government subsidies. The system is designed to ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...